TWST logo

Twist Bioscience Stock Price

Symbol: NasdaqGS:TWSTMarket Cap: US$2.1bCategory: Pharmaceuticals & Biotech

TWST Share Price Performance

Recent TWST News & Updates

No updates

Twist Bioscience Corporation Key Details

US$347.7m

Revenue

US$185.3m

Cost of Revenue

US$162.4m

Gross Profit

US$353.5m

Other Expenses

-US$191.1m

Earnings

Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 04, 2025
Earnings per share (EPS)
-3.19
Gross Margin
46.70%
Net Profit Margin
-54.98%
Debt/Equity Ratio
0%

Twist Bioscience Corporation Competitors

 
 
 
 
 
 
 
 
 
 
 
 

About TWST

Founded
2013
Employees
923
CEO
Emily Leproust
WebsiteView website
www.twistbioscience.com

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

U.S. Market Performance

  • 7 Days: -0.6%
  • 3 Months: 11.8%
  • 1 Year: 16.8%
  • Year to Date: 7.5%
In the last week, the market has been flat, with a notable exception in the Healthcare sector dropping 4.2%. More promisingly, the market is up 17% over the past year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading